ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Core Viewpoint - ProQR Therapeutics has initiated an underwritten public offering of its ordinary shares to fund research and development, clinical development, and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 15% of the offering amount at the public offering price [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1]. Group 2: Use of Proceeds - ProQR plans to utilize the net proceeds from the offering, along with existing cash, primarily for research and development and clinical development of current and future product candidates [2]. - Remaining funds will be allocated for working capital, capital expenditures, and other general corporate purposes [2]. Group 3: Regulatory Filings - A shelf registration statement on Form F-3 was filed with the SEC on September 30, 2024, and became effective on October 10, 2024 [3]. - A preliminary prospectus supplement will be filed with the SEC to describe the terms of the offering [3]. Group 4: Company Overview - ProQR Therapeutics focuses on transformative RNA therapies using its proprietary Axiomer™ RNA editing technology platform [5]. - The Axiomer™ technology aims to make specific single nucleotide edits in RNA, potentially leading to new medicines for both rare and prevalent diseases [5].